Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs
NCT ID: NCT02005146
Last Updated: 2015-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
86 participants
OBSERVATIONAL
2013-12-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HBsAg Declined Patients Follow-up Study
NCT05977283
Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory
NCT05376124
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
NCT00876148
"Real-life" Cohort of Patients With Chronic Hepatitis B Virus Infection
NCT01732081
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
NCT05965388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with chronic hepatitis B treated with nRTI
Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic hepatitis B (HBeAg+ or HBeAg-)
* HBsAg loss
* Treated with nucleoside/nucleotide analogues
* With or without previous interferon (IFN/PEG-IFN)
* Patients with HBsAg loss after 2006
* Immunocompetent patients
Exclusion Criteria
* HBsAg loss while treatment in monotherapy or combinated with IFN or PEG-IFN.
* Patients with hepatitis delta virus (HDV) coinfection.
* Patients with hepatitis C virus (HCV) coinfection.
* Patients with HIV coinfection.
* Patients with liver transplant.
* Patients with reactivated hepatitis B virus (HBV) by immuno-suppressive treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación Pública Andaluza Progreso y Salud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilio Suárez García
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Virgen de Valme
Miguel Ángel Simón Marco
Role: PRINCIPAL_INVESTIGATOR
Hospital Clínico Universitario Lozano Blesa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital Universitario Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Complejo Hospitalario Universitario Santiago
Santiago de Compostela, La Coruña, Spain
Hospital Severo Ochoa
Leganés, Madrid, Spain
Hospital Torrecárdenas
Almería, , Spain
Hospital Clínic
Barcelona, , Spain
Hospital del Mar
Barcelona, , Spain
Hospital Universitario Vall d'Hebron
Barcelona, , Spain
Hospital Universitario Reina Sofía
Córdoba, , Spain
Hospital Puerta de Hierro
Madrid, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Hospital de Navarra
Pamplona, , Spain
Hospital Donosti
San Sebastián, , Spain
Hospital Marqués de Valdecilla
Santander, , Spain
Hospital Universitario Virgen de la Macarena
Seville, , Spain
Hospital Universitario Virgen de Valme
Seville, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
Hospital Virgen de la Salud
Toledo, , Spain
Hospital General Universitario de Valencia
Valencia, , Spain
Hospital La Fe
Valencia, , Spain
Hospital Clínico Universitario Lozano Blesa
Zaragoza, , Spain
Hospital Miguel Servet
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESG-HEP-2013-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.